Alpha Tau Medical Ltd. (NASDAQ:DRTS – Get Free Report) CFO Raphi Levy sold 20,000 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $12.00, for a total value of $240,000.00. Following the completion of the sale, the chief financial officer directly owned 90,180 shares of the company’s stock, valued at approximately $1,082,160. The trade was a 18.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Raphi Levy also recently made the following trade(s):
- On Thursday, June 25th, Raphi Levy sold 20,000 shares of Alpha Tau Medical stock. The stock was sold at an average price of $11.00, for a total value of $220,000.00.
- On Tuesday, June 23rd, Raphi Levy sold 17,500 shares of Alpha Tau Medical stock. The shares were sold at an average price of $9.55, for a total transaction of $167,125.00.
- On Wednesday, June 3rd, Raphi Levy sold 32,500 shares of Alpha Tau Medical stock. The stock was sold at an average price of $10.83, for a total transaction of $351,975.00.
Alpha Tau Medical Stock Up 12.1%
Shares of NASDAQ DRTS opened at $12.58 on Wednesday. The company has a market capitalization of $1.14 billion, a P/E ratio of -18.78 and a beta of 1.19. Alpha Tau Medical Ltd. has a 52-week low of $2.87 and a 52-week high of $12.61. The company has a debt-to-equity ratio of 0.09, a quick ratio of 7.79 and a current ratio of 7.79. The company’s 50 day moving average price is $9.55 and its 200-day moving average price is $7.74.
Hedge Funds Weigh In On Alpha Tau Medical
Several institutional investors have recently made changes to their positions in DRTS. Renaissance Technologies LLC bought a new position in shares of Alpha Tau Medical during the 1st quarter worth about $286,000. Principal Financial Group Inc. bought a new stake in Alpha Tau Medical in the 1st quarter valued at about $132,000. Millennium Management LLC increased its position in Alpha Tau Medical by 185.7% in the 4th quarter. Millennium Management LLC now owns 107,815 shares of the company’s stock valued at $534,000 after buying an additional 70,081 shares in the last quarter. Mariner LLC increased its position in Alpha Tau Medical by 1.6% in the 4th quarter. Mariner LLC now owns 125,165 shares of the company’s stock valued at $620,000 after buying an additional 1,915 shares in the last quarter. Finally, Wells Fargo & Company MN raised its stake in Alpha Tau Medical by 291.7% during the 4th quarter. Wells Fargo & Company MN now owns 23,500 shares of the company’s stock worth $116,000 after buying an additional 17,500 shares during the period. Institutional investors and hedge funds own 2.65% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have recently weighed in on DRTS shares. Barclays lifted their price objective on Alpha Tau Medical from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday, June 4th. Piper Sandler raised their target price on Alpha Tau Medical from $5.00 to $8.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 19th. LADENBURG THALM/SH SH lifted their target price on Alpha Tau Medical from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of Alpha Tau Medical in a report on Tuesday, June 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Alpha Tau Medical in a research note on Monday, April 20th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $12.60.
View Our Latest Research Report on Alpha Tau Medical
Alpha Tau Medical Company Profile
Alpha Tau Medical Ltd. is a medical technology company headquartered in Ness Ziona, Israel, focused on developing targeted alpha-radiation therapies for the treatment of solid tumors. The company’s core innovation, known as Diffusing Alpha-emitters Radiation Therapy (DaRT), employs short-lived radioactive isotopes to deliver high-energy alpha particles directly within or adjacent to tumor tissues. By harnessing the potent cytotoxic effects of alpha radiation, Alpha Tau Medical aims to offer a novel approach to brachytherapy that can potentially overcome radioresistance and spare surrounding healthy tissue.
The company’s lead product, Alpha DaRT, is currently being evaluated in clinical studies for a range of indications including recurrent or metastatic head and neck cancers, skin cancers, and other solid tumors.
Featured Stories
- Five stocks we like better than Alpha Tau Medical
- Could Apple’s China Play Be the Answer to Its Memory Pressure Problem?
- 3 Charts That Could Change the Course of Summer Trading
- Burger King’s Turnaround Is Putting Restaurant Brands Back in Focus
- Short Squeeze Alert—Moderna Stock Surges on New Strategy
Receive News & Ratings for Alpha Tau Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpha Tau Medical and related companies with MarketBeat.com's FREE daily email newsletter.
